TNFA: TNF Pharmaceuticals, Inc. Company Value to Net Income

Corporate emblem and logo of TNF Pharmaceuticals, Inc. (TNFA)

TNF Pharmaceuticals operates within a stable US environment, where the medical profile of the business eliminates the impact of external political risks. TNF Pharmaceuticals relies on synergy with specialized funds to develop treatments for autoimmune pathologies and combat cellular senescence. The metric stands at -0.90. This chart on GURU.Markets demonstrates the price action of this innovator, which implements molecular therapy to correct inflammatory processes.

TNFA TNF Pharmaceuticals Inc.: Price to Earnings Ratio in the range 07/25/2024 - 09/25/2025

Comprehensive metric breakdowns and analytics for TNF Pharmaceuticals Inc. (TNFA)

- price and consensus price forecast:
Stock Price TNF Pharmaceuticals, Inc.|TNFA - Consensus Target
- market capitalization information:
Market Value TNF Pharma|TNFA - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share TNF Pharmaceuticals|TNFA - Company Net Assets|Market Cap to Book Value Multiple tnfpharma.com|TNFA - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio TNF Pharmaceuticals|TNFA - Long-Term Debt to Capital|Current Liabilities to Capital tnfpharma.com|TNFA - Company Debts|Debt to Net Assets Ratio TNF Pharmaceuticals, Inc.|TNFA - Company Long-Term Liabilities|Amount of Current Liabilities TNF Pharmaceuticals|Immediate Liquidity Ratio tnfpharma.com
- business earnings and investment ratios data:
TNFA - Net Profit|Forward Earnings TNF Pharmaceuticals|TNFA - Price to Earnings Ratio|Future Price to Earnings Multiple tnfpharma.com|TNFA - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio TNF Pharmaceuticals Inc.|TNFA - Operating profit EBITDA|Earnings per share for the trailing year TNF Pharmaceuticals|TNFA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth tnfpharma.com|TNFA - Earnings per share growth in current year|Expected earnings per share trend next year TNF Pharmaceuticals
- issuer revenue and sales details:
TNFA - Company Revenue|Company Future Sales Volume TNF Pharmaceuticals|TNFA - P/S Multiple|Forward P/S Multiple TNF Pharmaceuticals Inc.
Comprehensive company analysis:TNF Pharma - TNFA
Flagship merchandise of TNF Pharmaceuticals, Inc.

The P/E ratio measures the relationship between the market value of TNF Pharmaceuticals (TNFA) and its net income, determining the density of invested capital. Analyzing this metric allows for the identification of whether an asset is overvalued or if its earnings are undervalued. The adjusted P/E for TNF Pharmaceuticals on GURU.Markets visualizes the gap between market expectations and accounting reality. For TNF Pharmaceuticals, this indicator reflects the market value of patents for inflammation therapies. Stable demand in the geriatric segment makes this ratio a key measure of the business's long-term payback.

Competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|Theravance Biopharma - P/E Multiple|Market Cap to Net Income Ratio Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Price to Earnings Ratio|Price to Earnings Ratio Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E Multiple|Price to Earnings Multiple SXTC (China SXT Pharmaceuticals)|P/E Multiple EPRX|P/E Multiple bioharvest.com (BHST)|Price to Earnings Ratio Invizyne Technologies EXOZ|ORMP: Price to Earnings Multiple|ENTX: Price to Earnings Ratio|HYFT: Price to Earnings Ratio|ABVC BioPharma Inc. (ABVC) - Price to Earnings Ratio|cumberlandpharma.com (CPIX) - P/E Multiple|QNTM (Quantum BioPharma) - P/E Multiple|FGEN: Company Value to Net Income|P/E Multiple TELO|P/E Multiple Rani Therapeutics Holdings (RANI)|P/E Multiple SNYR (Synergy CHC Corp)|Rallybio Corporation (RLYB) - Market Cap to Earnings|LEXX - Price to Earnings Ratio|PULM (Pulmatrix) - Price to Earnings Multiple|Pheton Holdings Ltd (PTHL) - Price to Earnings Ratio|Aptorum - Company Value to Net Income|Price to Earnings Ratio LYRA|Price to Earnings Ratio Impact BioMedical Inc (IBO)|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)